Mebeverine not superior to placebo in pediatric IBS; active drug labeling improved efficacy

WASHINGTON — Mebeverine was not superior to placebo for the treatment of pediatric irritable bowel syndrome and functional abdominal pain, although active drug labeling significantly improved treatment success, researchers reported.
In a multicenter, double-blind trial, Marc A. Benninga, MD, PhD, professor of pediatric gastroenterology at Amsterdam UMC, and colleagues evaluated the safety and efficacy of the antispasmodic mebeverine, as well as the effect of labeling, among 268 children aged 12 to 18 years with IBS or functional abdominal pain not otherwise specified.
Researchers randomly

WASHINGTON — Mebeverine was not superior to placebo for the treatment of pediatric irritable bowel syndrome and functional abdominal pain, although active drug labeling significantly improved treatment success, researchers reported.
In a multicenter, double-blind trial, Marc A. Benninga, MD, PhD, professor of pediatric gastroenterology at Amsterdam UMC, and colleagues evaluated the safety and efficacy of the antispasmodic mebeverine, as well as the effect of labeling, among 268 children aged 12 to 18 years with IBS or functional abdominal pain not otherwise specified.
Researchers randomly